Aspirin or non‐steroidal anti‐inflammatory drug initiation and subsequent bladder cancer evaluation
Journal of Internal Medicine · 2026
DOI: 10.1111/joim.70115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, 2026. Verfasst von Malene Söth Hansen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Cancer Society, Kræftens Bekæmpelse.
Abstract (Originalsprache)
Background
Whether aspirin or non‐aspirin non‐steroidal anti‐inflammatory drugs (NSAIDs) initiation may unmask unknown bladder cancers (BCs) by hematuria remains controversial.
Objectives
To evaluate unmasking, we compared cystoscopy rates, BC prevalence at cystoscopy, and invasive stage prevalence at diagnosis in aspirin or NSAID initiators with never‐users.
Methods
Using the Danish population‐based registries, we identified all new aspirin or NSAID users in 2005–2023 and a matched never‐using comparison cohort. Second, we identified all first‐time cystoscopy recipients in 2005–2022 with aspirin or NSAID initiation within 1 year prior or never‐use in 10 years preceding cystoscopy. Comparing these groups, we computed hazard ratios of cystoscopy during 1‐year follow‐up, prevalence ratios of BC at cystoscopy, and invasive stage disease at diagnosis.
Results
Among 50,771 aspirin initiators (median age: 67 years, 51% men) and 156,191 NSAID initiators (age: 45 years, 50% men) adjusted hazard ratios of cystoscopy were 1.54 (95% confidence interval [CI]: 1.38–1.72) and 1.56 (95% CI: 1.43–1.70) compared with never‐users. Cystoscopy recipients included 683 aspirin (age: 70 years, 69% men) and 1414 NSAID initiators (age: 60 years, 63% men); standardized morbidity ratio weighted (SMRW) prevalence ratios were 0.97 (95% CI, 0.76–1.22) and 0.65 (95% CI, 0.51–0.82) compared with never‐users. The SMRW invasive stage prevalence ratios were 0.81 (95% CI, 0.63–1.03) and 1.07 (95% CI, 0.85–1.34) in the aspirin and NSAID comparison.
Conclusion
The combination of more cystoscopies and a lower prevalence of invasive stage at BC diagnosis may suggest the unmasking of asymptomatic BC in aspirin initiators. We did not find indications of unmasking with NSAID initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Department of Urology, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Malene Söth Hansen, Uffe Heide-Jørgensen, Mette Nørgaard
Förderung
- Danish Cancer Society
- Kræftens Bekæmpelse
Zitieren
APA
Hansen, M. S., Dyrskjøt, L., Heide-Jørgensen, U., Jensen, J. B., & Nørgaard, M. (2026). Aspirin or non‐steroidal anti‐inflammatory drug initiation and subsequent bladder cancer evaluation. Journal of Internal Medicine. https://doi.org/10.1111/joim.70115
Vancouver
Hansen MS, Dyrskjøt L, Heide-Jørgensen U, Jensen JB, Nørgaard M. Aspirin or non‐steroidal anti‐inflammatory drug initiation and subsequent bladder cancer evaluation. Journal of Internal Medicine. 2026. doi:10.1111/joim.70115
BibTeX
@article{Hansen2026,
author = {Hansen, Malene Söth and Dyrskjøt, Lars and Heide-Jørgensen, Uffe and Jensen, Jørgen Bjerggaard and Nørgaard, Mette},
title = {Aspirin or non‐steroidal anti‐inflammatory drug initiation and subsequent bladder cancer evaluation},
journal = {Journal of Internal Medicine},
year = {2026},
doi = {10.1111/joim.70115}
}
EUVIMED